Igenica

About Igenica

Igenica Biotherapeutics, Inc. was a biopharmaceutical firm established in 2008 and based in Burlingame, California, that concentrated on developing antibody-based cancer therapies. The company was co-founded by Dr. Robert Schreiber, an internationally recognized tumor immunologist from Washington University in St. Louis, and Dr. Guoqing Chen, who previously worked at Amgen and served as the VP of Research. Igenica's core mission was to address significant challenges in oncology by discovering new tumor antigens and developing effective antibody-drug conjugates (ADCs).

The company's business model was centered on its proprietary technology platforms designed for the discovery and development of cancer therapeutics. A key part of its strategy involved forming research collaborations with major pharmaceutical companies. For example, Igenica partnered with MedImmune, the biologics R&D arm of AstraZeneca, to evaluate ADCs targeting surface antigen in leukemia (SAIL). Under this agreement, Igenica provided its anti-SAIL antibodies and its SNAP ADC drug linker technology, while MedImmune supplied its anti-tumor payload. This business model allowed Igenica to leverage its specialized discovery engine while gaining access to the resources and expertise of larger partners, with revenue generated through option fees, upfront license fees, and potential milestone payments and royalties.

Igenica developed two primary technology platforms to drive its therapeutic pipeline. The first, sTAg (surface-tagged antigen profiling), was a proteomics-based technology for identifying new cancer-specific surface antigens suitable for antibody targeting. The second platform, iTAb (in vivo anti-tumor antibody screening), was a function-based method for screening monoclonal antibody candidates against these newly discovered antigens to find those effective at controlling or eliminating cancer. A significant component of its ADC technology was the proprietary SNAP linker, a chemically-driven method for creating homogeneous ADCs with a uniform drug-to-antibody ratio, which aimed to improve upon the heterogeneous mixtures of conventional ADCs. One of its leading candidates was IGN523, which was being advanced into early clinical trials for acute myelogeneous leukemia. The company ceased operations in October 2017.